Condition: Post-ERCP Acute Pancreatitis · Non-steroid Anti-inflammatory Drugs · Pancreatic Duct Stent Placement · Sponsor: Air Force Military Medical University, China
Pancreatitis is the most common and serious complication following post-endoscopic retrograde cholangiopancreatography (ERCP) and is associated with occasional mortality, extended hospital stays, and increased healthcare expenses. Rectal non-steroidal anti-inflammatory drugs (NSAIDs) and pancreatic duct stent (PDS) placement were demonstrated to be effective strategyies to reduce PEP incidences, particlularly in high-risk patients for post-ERCP pancreatitis (PEP). Rectal NSAIDs were easy-to-use and safe, while PDS placement were technically complex and carried higher risks of adverse events. A previous network meta-analysis suggested rectal NSAIDs in combination with PDS placement did not differ from rectal NSAIDs alone in PEP prevention. To invesigate if rectal NSAIDs alone could obivate the need of PDS placement, a recent trial from Elmunzer et al. conducted a randomized trial to investigate if rectal NSAIDs alone was non-inferior to the combination of NSAIDs with PDS in high-risk patients. The trial found that the PEP incidence rate in combination group was significantly lower than that in NSAIDs alone group. However, post-hoc analysis of the study suggested that the combination strategy conferred significant benefits only in high-risk patients with pancreatic duct (PD) wire passage, but not in those with other risk factors. Therefore, we hypothesized that rectal NSAIDs alone may obivate the need of PDS in high-risk patients without PD wire passages. Here, we conducted a …
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| The first medical center, Chinese PLA General Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Department of gastroenterology, Second Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| Department of Gastroenterology, Fujian Medical University Xiamen Humanity Hospital | Xiamen, Fujian, China | Recruiting |
| Harbin Medical University Affiliated Fourth Hospital | Harbin, Heilongjiang, China | Recruiting |
| The Second Affiliated Hospital of Harbin Medical University | Harbin, Heilongjiang, China | Recruiting |
| Department of Gastroenterology, Huaihe Hospital of Henan University | Kaifeng, Henan, China | Recruiting |
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| The Third Xiangya Hospital of Central South University | Changsha, Hunan, China | Not Yet Recruiting |
| 986 Hospital of Xijing Hospital | Xi'an, Shaanxi, China | Recruiting |
| Xijing of Digestive Diseases | Xi'an, Shaanxi, China | Recruiting |
| Department of Gastroenterology, The 960th Hospital of the PLA | Jinan, Shandong, China | Recruiting |
| Shandong Provincial Third Hospital | Jinan, Shandong, China | Not Yet Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07117318